This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

6 Feb 2014

Absence of Blockbuste?r Drug Launches in 2014 Puts R&D Productivi?ty at Risk

The past 2 years have brought a surge of R&D productivity, driving investor confidence and increasing market performance, but 2014 looks to tell a different tale according to the new report, “Biggest Launches 2014,” from EP Vantage.


Only three drugs slated to launch this year will achieve blockbuster status by 2018. A disappointing number compared with the 10 new molecules approved in 2013. This could all change, however, should Merck and Bristol-Myers Squibb’s anti-programmed death-1 (PD-1) antibodies reach the market this year, according to the new report.


The report also includes an analysis of 5th Year Sales of launches between 2004 and 2014, utilising EvaluatePharma consensus forecasts showing the industry’s biggest hits and misses.


“While the launch timetable for 2013 performed as expected, several products saw their forecasts increase and with an incredible class of eight to 10 drugs slated to become blockbusters, 2013 proved to be a tough act to follow,” said  Jonathan Gardner, report author and EP Vantage deputy news editor. “The class of 2014 will fail to match last year’s high mark. And with giant new products needed to restore faith in R&D productivity, how the lack of blockbuster drug launches will affect investor’s views of the biotech sector will be one of the interesting stories of this year.”


Among the report’s key findings:

• The forecasted blockbusters of 2014 include: GlaxoSmithKline’s combination COPD therapy, Anoro Ellipta, Lundbeck’s Brintellix for major depressive disorder and Celgene’s psoriatic athritis drug, Apremilast

• Diabetes is forecasted to be the biggest category of products set to launch in 2014 with oncology and anti-infectives also well represented on the list

• Although small molecules still dominate new medicines, 2014 could be one of the biggest years for biological drug launches, particularly if the PD-1 antibodies make it to market

• The industry’s move to “nichebuster” drugs may explain the switch from blockbuster drug development, but billion-dollar drugs remain an indicator of the sector’s productivity.


The “Biggest Launches 2014” report, based on market intelligence and analysis from EvaluatePharma, can be downloaded at

Related News